Production and tumour uptake of [64Cu]pyruvaldehyde-bis (N 4-methylthiosemicarbazone) for PET and/or therapeutic purposes

Nuclear Medicine Review

Volumn 10, Issue 1, 2007, Pages 6-11

  Jalilian, Amir Reza ^a   Rowshanfarzad, Pejman ^a   Kamrani, Yousef Yari ^a   Shafaii, Kamaleddin ^a   Mirzaii, Mohammad ^a  

^a Nuclear Research Center for Agriculture and Medicine NRCAM   (Iran)

Author keywords

Copper 64; Fibrosarcoma; PET; PTSM; Targeted therapy

Indexed keywords

COPPER; COPPER (II) PYRUVALDEHYDE BIS(N(4) DIMETHYLTHIOSEMICARBAZONE); COPPER (II) PYRUVALDEHYDE BIS(N(4)-DIMETHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DRUG STABILITY; MOUSE; POSITRON EMISSION TOMOGRAPHY; SARCOMA; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; COPPER RADIOISOTOPES; DRUG STABILITY; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA, EXPERIMENTAL; THIOSEMICARBAZONES; TISSUE DISTRIBUTION;

EID: 34548545284     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. J Nucl Med Biol 1996; 23: 957-980. (Pubitemid 27050682)
2. Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Advanc Drug Deliver Rev 1999; 37: 189-211. (Pubitemid 29164508)
3. Maa D, Lua F, Overstreeta T, Milenica DE, Brechbiela MW. Novel chelating agents for potential clinical applications of copper. J Nucl Med Biol 2002; 29: 91-105.
4. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995; 36: 2315-2325.
5. 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm 2004; 19: 25-34.
6. 64Cu- labeled dimeric RGD peptides. Mol Imaging Biol 2004; 6: 350-359.
7. 64Ni enriched nickel target. Appl Radiat Isot 2002; 57: 773-777.
8. Mathias CJ, Welch MJ, Raichle ME et al. Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM. J Nucl Med 1990; 31: 351-359. (Pubitemid 20090805)
9. Mathias CJ, Welch MJ, Perry DJ et al. Investigation of copper-PTSM as a PET tracer for tumour blood flow. Nucl Med Biol 1991; 18: 807-811.
10. Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Kinetics of Copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med 1989; 30: 1843-1847.
11. Green MA, Klippenstein DL, Tennison JR. Copper(II) Bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med 1988; 29: 1549-1557.
12. 64Cu]DTPA: new radiopharmaceuticals for quantitative tomocisternography. Appl Radiat Isot 1983; 34: 595-601.
13. Green MA. A potential copper radiopharmaceutical for imaging the heart and brain: copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone). Nucl Med Biol 1987; 14: 59-61. (Pubitemid 17030184)
14. Kostyniak PJ, Nakeeb SM, Schopp EM, Maccubbin AE, John EK, Green MA, Kung HF. Acute toxicity and mutagenicity of the copper complex of pyruvaldehyde-bis (N-4-methylthiosemicarbazone), Cu-PTSM. J Appl Toxicol 1990; 10: 417-421. (Pubitemid 20386401)
15. Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. Circulation 1990; 82: 990-997. (Pubitemid 20316751)
16. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med 1994; 21: 336-341. (Pubitemid 24106452)
17. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Tissue blood flow estimation with copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) and PET. J Nucl Biol Med 1994; 38: 89-91.
18. Adonai N, Nguyen KN, Walsh J et al. Ex vivo cell labelling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 2002; 99: 3030-3035. (Pubitemid 34240580)
19. 64Ni targets for positron emission tomography. Appl Radiat Isot 1991; 42: 193-197.
20. 64Cu at a small cyclotron. Appl Radiat Isot 1993; 44: 575-580.
21. 67Cu process. Appl Radiat Isot 2003; 59: 343-351.
22. Boothe TE, Tavano E, Munoz J, Caroll S. Coproduction of Copper-64 and Copper-67 using protons on Zinc-68. J Label Comp Radiopharm 1991; 30: 108.
23. Ziegler JF, Biersack JP, Littmark U. The stopping and range of ions in matter (SRIM Code). 2000; Version 2000 XX.
24. Gingras BA, Suprunchuk T, Bayley CH. The preparation of some thiosemicarbazones and their copper complexes. Can J Chem 1962; 40: 1053-1057.
25. th ed. Ellis Horwood Ltd., Chichester 1976: 369.
26. Wallhaus TR, Lacy J, Whang J, Green MA, Nickles RJ, Stone CK. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM. J Nucl Med 1998; 39: 1958-1964. (Pubitemid 28518899)